We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Complete Blood Count Risk Score Predict Life Expectancy

By LabMedica International staff writers
Posted on 05 Dec 2013
A simple blood test may predict who is at the highest risk to develop heart problems and how long these people may have to live. More...


The complete blood count (CBC) risk score is an inexpensive tool that uses all of the information in the common blood test, which includes laboratory data that is frequently underused.

Scientists at the Intermountain Medical Center Heart Institute (Murray, UT, USA) collaborating with those at Brigham and Women's Hospital (Boston, MA, USA) used CBC laboratory testing information gathered as part of the Justification for the Use of Statins in Primary Prevention (JUPITER) Trial, a randomized clinical trial of a cholesterol-lowering drug.

The JUPITER study enrolled more than 17,000 individuals in 26 countries and followed them for up to five years. Participants in JUPITER had a clean slate free of cardiovascular disease normal low-density-lipoprotein cholesterol, but elevated C-reactive protein, a marker of inflammation associated with cardiovascular disease.

Individuals in the trial with a lower CBC risk score were very unlikely to die, while those with CBC risk scores in the middle of the range had more than 50% higher risk of death. People with the highest CBC risk scores were about twice as likely to die as those with low scores. The CBC risk score and its parent risk score, the Intermountain Risk Score, which is a combination of the CBC laboratory test and the basic metabolic profile blood test, were created to provide useful health information to allow physicians to easily compute the risk score while continuing to care for patients.

Benjamin Horne, PhD, director of cardiovascular and genetic epidemiology at the Intermountain Medical Center, said, “We now have a standardized way of assessing the risk of mortality for all individuals, not just ones with a history of heart diseases. One of the beauties of this score is it uses clinically familiar, standardized medical information already in electronic format. The financial cost is also almost zero because most patients already receive the CBC test. The clinical cost is also low, because of electronic medical records. Physicians receive this critical information about future risk, which adds to their knowledge about the patient, while it takes very little of their time or effort to obtain the information.” The study was presented at the American Heart Association Scientific Sessions, held November 16-20, 2013, in Dallas (TX, USA. 

Related Links:
Intermountain Medical Center Heart Institute
Brigham and Women's Hospital 


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.